Gyre Therapeutics (GYRE) Proxy Filing summary

Executive summary

• Annual meeting scheduled for June 4, 2025, to be held virtually for shareholder participation.

• Shareholders are encouraged to review proxy materials online or request copies by May 21, 2025.

Voting matters and shareholder proposals

• Election of three Class I Directors for terms expiring in 2028: Gordon Carmichael, Ph.D., Songjiang Ma, and Ping Zhang.

• Advisory vote to approve compensation of named executive officers.

• Ratification of Grant Thornton Zhitong Certified Public Accountants LLP as independent auditor for 2025.

• Board recommends voting in favor of all proposals.

Board of directors and corporate governance

• Board nominees for Class I Directors are listed for election to serve until 2028.